Literature DB >> 8537669

Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma.

S Chuck1, R M Grant, E Katongole-Mbidde, M Conant, D Ganem.   

Abstract

While Kaposi's sarcoma (KS) is extremely common in homosexual men infected with human immunodeficiency virus (HIV), it is also found in several clinical settings in which HIV infection is absent. Recently, sequences from the genome of a novel member of the herpesvirus family have been identified within KS biopsies in the AIDS-associated form of the disease. The presence of these sequences was sought in 6 cases of HIV-negative KS, including 4 cases of endemic KS from Africa, and was found in 5 of the 6. These findings strengthen the association between infection with this virus and the development of KS and argue against the notion that this association is simply the result of opportunistic superinfection of profoundly immunodeficient hosts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8537669     DOI: 10.1093/infdis/173.1.248

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations.

Authors:  J C Zong; D M Ciufo; D J Alcendor; X Wan; J Nicholas; P J Browning; P L Rady; S K Tyring; J M Orenstein; C S Rabkin; I J Su; K F Powell; M Croxson; K E Foreman; B J Nickoloff; S Alkan; G S Hayward
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus.

Authors:  V Varthakavi; P J Browning; P Spearman
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma.

Authors:  W Zhong; H Wang; B Herndier; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells.

Authors:  Jinjong Myoung; Don Ganem
Journal:  Virology       Date:  2011-02-25       Impact factor: 3.616

5.  The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions.

Authors:  R Renne; M Lagunoff; W Zhong; D Ganem
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 6.  Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.

Authors:  C Boshoff; R A Weiss
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  Chuang-Jiun Chiou; Lynn J Poole; Peter S Kim; Dolores M Ciufo; Jennifer S Cannon; Colette M ap Rhys; Donald J Alcendor; Jian-Chao Zong; Richard F Ambinder; Gary S Hayward
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells.

Authors:  Lei Chen; Michael Lagunoff
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 9.  Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate.

Authors:  J Doniger; S Muralidhar; L J Rosenthal
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

10.  Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.

Authors:  Bo Xu; Ling Wang; Lorenzo González-Molleda; Yan Wang; Jun Xu; Yan Yuan
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.